The S&P/ASX 200 index is home to many high-quality blue chip shares. These are companies with strong market positions, reliable earnings, and solid long-term growth prospects.
But which blue chips could be top buys right now?
Let's take a look at three that analysts think could be worth considering this month. They are as follows:
Image source: Getty Images
REA Group Ltd (ASX: REA)
The first blue chip ASX 200 share that could be a buy is REA Group.
It is the dominant player in Australia's online real estate advertising market. It owns and operates realestate.com.au, the country's most-visited property website, which gives it a powerful moat and pricing power.
Despite cyclical fluctuations in the property market, REA Group has consistently delivered growth thanks to its high-margin digital business model and expanding product suite for agents, developers, and consumers.
UBS is a big fan of REA Group and has a buy rating and $290.00 price target on its shares.
ResMed Inc (ASX: RMD)
Another ASX 200 blue chip share to consider is ResMed.
It is a global leader in sleep and respiratory care, with a growing portfolio of connected devices and software solutions. The company has built a strong competitive position in treating sleep apnoea and related conditions — a market supported by rising global awareness, ageing populations, and increasing diagnosis rates.
ResMed's scale, brand trust, and proprietary digital ecosystem (including cloud-based patient data and remote monitoring tools) make it hard for competitors to match its offering. This leaves it well-positioned for growth in a market estimated to comprise over 1 billion people.
For investors looking for a globally exposed healthcare stock with defensive traits and strong secular tailwinds, ResMed could be an attractive option at current levels.
Macquarie has an outperform rating and $48.00 price target on ResMed's shares.
Treasury Wine Estates Ltd (ASX: TWE)
Finally, Treasury Wine Estates could be an ASX 200 blue chip share to buy.
It is one of the world's largest premium wine companies, with iconic brands such as Penfolds, Wynns, and 19 Crimes under its belt. It has undergone significant transformation in recent years, pivoting away from lower-margin commercial wines toward a premium and luxury-focused strategy.
That shift is starting to pay off, though some of this is being masked by tough trading conditions. Penfolds continues to perform strongly, particularly in Asia, where the reintroduction of Australian wine into the Chinese market presents a meaningful growth opportunity. The acquisition of DAOU Vineyards has also strengthened Treasury's position in the US luxury wine segment.
So, with its shares down sharply over the past 12 months, now could be a great time for patient investors to snap them up. Morgans thinks this is the case and recently put a buy rating and $10.25 price target on its shares.
